Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2401MR)

This product GTTS-WQ2401MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2401MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2321MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ10777MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ9891MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ5901MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ12568MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ13331MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ11790MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW